<DOC>
	<DOCNO>NCT01023958</DOCNO>
	<brief_summary>The primary objective trial evaluate efficacy safety BI 6727 patient locally advance , metastatic recurrent urothelial cancer failure first line adjuvant/neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Intravenous BI 6727 ( Volasertib ) 2nd Line Treatment Urothelial Cancer</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Histologically cytologically confirm urothelial cancer bladder , ureter renal pelvis . 2 . Patients stage III , IV recurrent urothelial cancer bladder , ureter renal pelvis failure recurrence first line adjuvant/neoadjuvant chemotherapy . Recurrence define relapse within 2 year cessation prior firstline chemotherapy . 3 . Male female patient age 18 year old 4 . Life expectancy least three ( 3 ) month 5 . Eastern Cooperative Oncology Group performance score 2 less 6 . At least one target tumor lesion irradiate within past three month accurately measure magnetic resonance imaging ( MRI ) compute tomography ( CT ) least one dimension ( long diameter record ) &gt; 20 mm conventional technique &gt; 10 mm spiral CT 7 . The patient must give write informed consent prior inclusion trial must consistent International Conference Harmonization , Good Clinical Practice ( ICHGCP ) local legislation Exclusion criterion : 1 . More one prior regimen chemotherapy include prior adjuvant therapy 2 . Brain metastases 3 . Patients bone metastasis site disease exclude 4 . Serious illness organ system dysfunction , opinion investigator , would either compromise patient safety , interfere evaluation safety test drug limit compliance trial requirement . 5 . QTc prolongation deem clinically relevant investigator 6 . Second malignancy currently require active therapy 7 . Other active malignancy diagnose within past 3 year ( non melanomatous skin cancer cervical intraepithelial neoplasia ) 8 . Absolute neutrophil count ( ANC ) &lt; 1,500/µl 9 . Platelet count &lt; 100,000/µl 10 . Hemoglobin &lt; 9 g/dl 11 . Total bilirubin &gt; 1.5 mg/dl 12 . Aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 2.5 x ULN , aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 5 x ULN case know liver metastases 13 . Serum creatinine &gt; 1.5 x ULN 14 . Chemo , Radio immunotherapy within past 4 week . This apply steroid bisphosphonates . 15 . Active infectious disease , HIV , HepatitisB C infection 16 . Active drug alcohol abuse 17 . Women men sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner participate female , condom participate male ) trial 18 . Pregnancy breast feed 19 . Treatment investigational drug within past 4 week within less four halflife time investigational drug treatment trial drug and/or persistence toxicity prior anticancer therapy deem clinically relevant . 20 . Prior treatment Pololike kinase 1 ( Plk1 ) inhibitor 21 . Patient unable comply protocol 22 . Any known hypersensitivity trial drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>